Access For Patients In Developing Countries

Tibotec Pharmaceuticals granted three non-exclusive licenses to Hetero Drugs Ltd and Matrix Laboratories Ltd of India and Aspen Pharmacare of South Africa to manufacture, market and distribute the investigational drug TMC278.Tibotec Pharmaceuticals granted three non-exclusive licenses to Hetero Drugs Ltd and Matrix Laboratories Ltd of India and Aspen Pharmacare of South Africa to manufacture, market and distribute the investigational drug TMC278.

Under the agreement, the generic manufacturers will be entitled to manufacture once-daily 25 mg TMC278 as a single agent medicine and a fixed-dose combination (FDC) product. Fixed-dose combinations contain multiple medicines formulated into one tablet helping to simplify HIV therapy and are preferred by public health treatment programs.

This is an extremely exiting milestone in our efforts to provide our HIV medicines to patients in developing countries. It marks the first phase of our larger global access and partnerships strategy for TMC278.

We're moving quickly to establish mechanisms to broaden access to TMC278 - starting even before we have final regulatory approval in the U.S. or Europe - to ensure that all patients in need, not merely those in developed countries, have access to our newest medicines.

A cornerstone of our Global Access & Partnerships Program (GAPP), voluntary licensing plays a vital role in ensuring widespread, sustainable access to our medicines where they're needed most.

Tibotec Pharmaceuticals, based in Cork, Ireland, is a pharmaceutical research and development company and one of the companies that compose the Janssen Pharmaceutical Companies of Johnson & Johnson. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need.